Volume 18, Issue 3 (Aug-Sep 2014)                   2014, 18(3): 54-63 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Bakhtiari N, Saadatnia G. RNA based antisense drugs: different types, molecular mechanisms and clinical trials. Journal of Inflammatory Diseases. 2014; 18 (3) :54-63
URL: http://journal.qums.ac.ir/article-1-1612-en.html
1- , nbakhtiari@irost.org
2- Iranian research organization for science and technology, biotechnology department
Abstract:   (8266 Views)

  A few decades ago, drugs which were used to treat different diseases were only limited to chemical drugs, peptides, monoclonal antibodies and recombinant proteins. Since the first nucleotide drug was approved by the Food and Drug Organization of the United States, this new generation of medications became remarkable to researchers and pharmacists . Ribonucleic acid ( RNA) based drugs were among these category that encountered a number of hurdles along the way such as potential immunogenicity, structural instability and the need for a vehicle to deliver the drug into the cell . With regards to the simplicity of the RNA therapeutics design, researchers could overcome the challenges with improvements in synthetic delivery carriers and chemical modifications of the RNA therapeutics. Numerous types of RNA-based drugs are being extensively tested in various stages of clinical trials. This review focuses on therapeutic ribozymes, antisense oligonucleotides, interfering RNAs and aptamers.

Full-Text [PDF 227 kb]   (6135 Downloads)    
Type of Study: Review article | Subject: Pharmacology

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 CC BY-NC 4.0 | Journal of Inflammatory Diseases

Designed & Developed by : Yektaweb